CXCR4 and leukemia: This is in line with other (clinical) studies showing promising results by inhibiting CXCR4 in AML or even proposing that the blockade of CDK family members, e.g., with palbociclib, could be a beneficial treatment option in combination with NOTCH1 inhibition for leukemia [2,35,51,52].